We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Webinars

Now get all the training you need – all in one place, and all for one low price!

The FDAnews Webinar Training Pass program gives you year-round unrestricted access to any of the hundreds of webinars listed below. These training programs feature top consultants, expert speakers and FDA officials.

PLUS, subscribers get automatic access to all our new training programs for the next 12 months – that’s more than 50 new programs a year!

If you are already a Training Pass member login below and then scroll down to view the list in date order or narrow your search by keyword or category. Viewing the webinar is easy… simply identify the webinar you want to watch, click on the title and the video will begin. If you would like to view or download the presentation materials separately from the video click the "Download Presentation" link.

LOGIN

BUY NOW Single-User 1-Year Unlimited Access $1,297

Also available: Take advantage of our multi-user and site licenses of the Webinar Training Pass, so you’ll have the most-informed workforce! Contact Will Tuttle, Business Development Representative at wtuttle@fdanews.com or +1 612.216.2948 to receive a custom quote.

Search by keyword, speaker name or just by category (drug, device or clinical) and you'll find all you need.

If you have any questions or are having any problems please give us a call on 703.538.7600 or email customer service.

Webinar Training Pass

Beginning with the End in Mind: Inspection Readiness — A Sponsor’s Perspective
52 minutes

Recorded on: Dec. 15, 2022

Description: Donna Dorozinsky shares a strategy for identifying key parts that represent your study’s unique inspection risks, what you can do now to become more inspection prepared and the key processes you can put into place at study start-up so you’re continually inspection-prepared. You’ll learn:

  • How to identify key study activities where inspection risk may exist;
  • An approach that allows you to understand your study’s story even if you were not a participant in the management of the study;
  • How to identify key processes to put in place at study start-up to ensure that inspection preparation is integral to routine business; and
  • Ideas for better inspection preparation.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Donna Dorozinsky, President and CEO, Just in Time GCP

Gene & Cell Therapy Regulation: Comparability and Other New Developments
90 minutes

Recorded on: Dec. 14, 2022

Description: This webinar enables you to understand and comply with the FDA’s requirements and avoid common errors, so you can maintain your products’ critical quality attributes (CQAs) and bring them to market. You’ll learn:

  • FDA requirements for comparability studies for gene and cell therapy products;
  • Best practices for risk analysis and mitigation using comparability studies;
  • How to design an effective comparability protocol for a gene or cell therapy product;
  • How to construct a statistical approach to comparability; and
  • How to assemble the comparability package to comply with FDA requirements.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Scott R. Burger, MD, Principal, Advanced Cell & Gene Therapy; and William E. Janssen, PhD, Principal, WEJ Cell and Gene Therapy Consulting Services

Building a World-Class Regulatory Intelligence and Support System: What Regulatory, Compliance and Quality Professionals Need to Know
63 minutes

Recorded on: Dec. 13, 2022

Description: Dennett Kouri and Faviola Michelot detail how to build a regulatory intelligence management system that will enable you to stay ahead of the changes and stay compliant, sharing:

  • What regulatory intelligence is and how you can develop and implement it;
  • What resources are needed to support regulatory intelligence;
  • The new regulatory trends you must have on your radar; and
  • How to pursue engaging opportunities with regulators.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Dennett Kouri, Senior Vice President, Edwards Lifesciences; and Faviola Michelot, Senior Director, Edwards Lifesciences

Engaging with the FDA: Best Practices for Dealing with Warning Letters, Seizures, Injunctions — and More
68 minutes

Recorded on: Dec. 1, 2022

Description: Steve Silverman, president of The Silverman Group — and previous director of the Center for Devices and Radiological Health’s (CDRH) Office of Compliance and assistant director of the Center for Drug Evaluation and Research’s (CDER) Office of Compliance — shares how to engage effectively with the FDA. He’ll cover:

  • What effective FDA regulatory engagement means as well as misperceptions to be aware of;
  • The four essential principles of effective regulatory engagement: informed, trust-based, timely, appropriate;
  • The three steps to achieve effective regulatory engagement; and
  • How novel issues like digital technology and real-world evidence influence effective regulatory engagement.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Steve Silverman, President, The Silverman Group

The Unification Impact: The Unique Benefits of One System that Replaces Many
50 minutes

Recorded on: Nov. 30, 2022

Description: Take control of compliance and data integrity to accelerate research and development from drug discovery to clinical processes through a unified compliance management solution. Learn how to:

  • Unify and connect disparate systems and processes together within your quality and compliance system to mitigate risks and increase efficiencies; and
  • Integrate total compliance, quality, and risk management system that will not only replace 10–12-point solutions into one unified solution but also provides a collaborative environment that saves time and speeds up product launches.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Anu Ganguly, Senior Director, Strategic Client Partner, Xybion; and James Castonguay, Assistant Vice President, Product Development, Xybion

Writing CAPAs the Right Way
35 minutes

Recorded on: Nov. 29, 2022

Description: Effective CAPA implementation needs effective problem communication with team members, clear description of actions and clear goals. Learn how to:

  • Communicate corrective actions in a manner to ensure compliance;
  • Outline typical CAPA writing problems; and
  • Steps to follow to structure effective CAPA’s.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Judith Meritz, Life Sciences Regulatory Consultant, Meritz & Muenz LLP

MDUFA Reauthorization Developments: What Regulatory, Compliance and Quality Professionals Need to Know
54 minutes

Recorded on: Nov. 10, 2022

Description: Jessica Ringel sheds light on the changes in user fees, the commitments the FDA’s Center for Devices and Radiological Health (CDRH) has made to the device industry in connection with its performance on marketing applications and related premarket processes — and what that could mean for you — and she’ll discuss what comes next for the unenacted legislation, including:

  • How to budget for future marketing applications by understanding the increases in user fees being assessed for device applications;
  • CDRH’s timeline commitments so you can better anticipate its marketing application review and the potential effects on timing of new device market launches; and
  • When to expect certain guidance documents the FDA has promised to issue over the next few years as part of its MDUFA V commitments, including revisions to the guidance documents on real-world evidence and presubmissions.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Jessica Ringel, Partner, King & Spalding

Charging for Investigational Drugs and Devices: What You Must Know About Opportunities and Pitfalls in Recovering Direct Costs
56 minutes

Recorded on: Nov. 9, 2022

Description: Of counsel Paul Gadiock, who was a former associate center director for policy at the FDA’s Center for Devices and Radiological Health, and associate Olivia Cusimano — both with Wilson Sonsini Goodrich & Rosati — clarify the FDA’s current stance on charging for investigational drugs and devices. And they share:

  • The factors to consider when deciding whether to seek cost recovery from participants in different clinical trial phases, such as retaining runway revenue and maintaining adequate recruitment;
  • Which investigational drug expenses can be recovered without FDA authorization, which can only be recovered with FDA authorization and which cannot be recovered at all; and
  • The documentation requirements for sponsors to receive FDA authorization for cost recovery under the agency’s most recent guidance, Charging for Investigational Drugs Under an IND: Questions and Answers.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Paul Gadiock, Of Counsel, Wilson Sonsini Goodrich & Rosati; and Olivia Cusimano, Associate, Wilson Sonsini Goodrich & Rosati

PDUFA and BsUFA Reauthorization Developments: What Regulatory, Compliance and Quality Professionals Need to Know
60 minutes

Recorded on: Nov. 8, 2022

Description: Jessica Greenbaum, counsel in King & Spalding’s FDA and Life Sciences practice and former regulatory counsel in the FDA’s Office of Therapeutic Biologics and Biosimilars, walks you through the potential fate of the remaining provisions so you’ll be ready when — or if — the initiatives of most importance to you finally take effect. She provides:

  • An overview of the bare-bones user fee package Congress enacted on Sept. 30, 2022;
  • A deeper understanding of the key drug- and biologics-related riders that accompanied the original House and Senate bills, including those related to accelerated approval and diversity in clinical trials; and
  • Insight into the potential consequences and impacts of these provisions, including how the proposal to amend the first interchangeable exclusivity provisions could facilitate competition.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Jessica Greenbaum, Counsel, King & Spalding

QMS Considerations: Real-World Evidence (RWE) Program
58 minutes

Recorded on: Nov. 2, 2022

Description: IQVIA principal consultant and former FDA official Jan Pierre reveals how to build a RWE QMS, including insights on:

  • What the regulatory landscape looks like for RWE, particularly the FDA’s Quality Framework to support a new drug or device regulatory filing;
  • What programmatic changes you must adopt to set up a RWE program;
  • The study feasibility process and its relationship to achieving “evidence quality”, including examples of study feasibility parameters; and
  • How to identify new RWE-related roles and responsibilities.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Jan Pierre, Principal Consultant, IQVIA

Previous 1 2 3 4 5 6 7 8 9 … 75 76 Next

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • BioVentrix gets Expanded Access Approval for Left Ventricle Support System

  • FDA Approves Stemline’s Orserdu for Several Forms of Breast Cancer

  • FDA Issues Update on LivaNova Recall of Blood Pumping System

  • EU Expands Dupixent’s Authorization to Include Eosinophilic Esophagitis

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing